R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Feb

Today In Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

A Paradigm Shift In Treating Adult AML?

Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says

VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer

Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans

FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency